BioMotion Suite was a startup that developed a motion analysis app to help doctors better manage physically disabled patients. We developed novel machine-learning software that measured how Parkinson patients respond to drug therapy using the smartphone motion sensor (accelerometer), worn in a pocket. We validated the software in a clinical study with physician leaders from Columbia University Medical Center and explored industry collaborations with 2 leading drug and device companies. This led to a 2-year mobile development project with the National Parkinson Foundation.
We ultimately discontinued due to difficulty fundraising. We learned that BioMotion would have required too much time and money to validate our business model. Since we planned to partner with drug companies for sales/distribution, we discovered in talks with commercial partners that more extensive clinical validation and FDA clearance would be needed before possibly entering into partnership deals.